<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T00:53:12Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/12901" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/12901</identifier><datestamp>2026-09-24T22:09:07Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Niles, Len</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Foster, Jane</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Sakic, Boris</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Sathiyapalan, Arani</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Sciences (Neuroscience and Behavioral Science)</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-06-18T17:01:11Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-06-18T17:01:11Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="created" lang="en_US">2013-04-04</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">2013-04</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">opendissertations/7748</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">8807</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">3995577</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/12901</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/23175</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">&lt;p>Valproic acid (VPA) is clinically utilized as an anti-convulsant and mood stabilizer, though its mechanism of action has not been fully elucidated.&lt;strong> &lt;/strong>Evidence suggests an interaction between VPA and the melatonergic system as VPA up-regulated the melatonin MT&lt;sub>1&lt;/sub> receptor subtype in rat C6 glioma cells. To determine if the observed effects can translate to an &lt;em>in vivo &lt;/em>model, we investigated the effects of chronic VPA administration in a rat model on the expression of MT&lt;sub&gt;1&lt;/sub> and MT&lt;sub>2&lt;/sub> receptors in the hippocampus. We also investigated the effect of chronic VPA treatment on the expression of the neurotrophic factors BDNF and GDNF in the rat hippocampus and striatum.&lt;/p> &lt;p>(1) Animals were separated into two groups with the experimental group receiving VPA (4 mg/mL) for 17 days, and the control receiving vehicle. The hippocampus was dissected and MT&lt;sub>1&lt;/sub>, MT&lt;sub>2&lt;/sub>, BDNF and GDNF mRNA were analyzed with RT-PCR. (2) Animals were separated into three groups with the first group receiving VPA (4 mg/mL), the second receiving VPA (3 mg/mL) for 16 days, and the control receiving vehicle. MT&lt;sub>2&lt;/sub> mRNA in the hippocampal subregions were analyzed with in situ hybridization.&lt;/p> &lt;p>VPA induced the expression of MT&lt;sub>1&lt;/sub> and MT&lt;sub>2&lt;/sub> mRNA in the hippocampus in the experimental group compared to the control group. VPA also increased MT&lt;sub>2&lt;/sub> mRNA expression in the subregions of the hippocampus. Additionally, BDNF and GDNF mRNA expression were increased in the VPA treatment group.&lt;/p> &lt;p>These findings raise the interesting question of whether the diverse clinical effects of VPA involve an interaction with the melatonergic system.&lt;/p></dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Valproic acid</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">melatonin</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">melatonin receptors</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">GDNF</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">BDNF</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">HDAC inhibitor</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">epigenetic</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">in vivo</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Molecular and Cellular Neuroscience</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Neuroscience and Neurobiology</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Molecular and Cellular Neuroscience</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">EFFECTS OF VALPROIC ACID ON EXPRESSION OF THE MELATONIN RECEPTORS MT1 AND MT2, AND THE NEUROTROPHIC FACTORS BDNF AND GDNF IN VIVO</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>